Diagnosis and Treatment of Autoimmune Pancreatitis: Analysis of Six Cases
Mei Jin-hua,Cai Xiu-jun,Liang Xiao,Wu Jia-guo,Zheng Wei-liang,Zhang Qiao-wei
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20113249
IF: 6.133
2013-01-01
Chinese Medical Journal
Abstract:Autoimmune pancreatitis (AIP) is a rare and special type of chronic pancreatitis, which was earlier referred to as lymphoplasmacytic sclerosing pancreatitis (LPSP), idiopathic duct destructive pancreatitis, or granulocyte epithelial lesion-positive pancreatitis. The concept of AIP was not coined by Yoshida until 1995.1 Although AIP was initially reported in Japan, USA and Europe, AIP cases have increased rapidly in China in the last few years. According to statistics, AIP accounts for 2.2%-2.4% of pancreatectomy and 19.5%-28.0% of benign pancreatic operation.2 Because AIP is induced by autoimmune mechanism, oral steroid therapy is usually effective and most of the time operation is unnecessary. In order to deepen our understanding about the diagnosis and treatment of AIP, to reduce the chances of unwanted operation, we retrospectively analyzed AIP cases admitted to our hospital in the recent years. METHODS Patients There were six patients, including four male and two female, with an averaged age of 63 (50-75) years, admitted to our hospital from July 2008 to September 2011. All the cases were confirmed by the Asian AIP diagnosis criteria revised in 2008.3 Diagnosis methods After admission, CBC, GPT, GOT, bilirubin, amylase, IgG or IgG4, CEA, CA199, ANA values were observed in all patients. B ultrasound (BUS), computed tomography (CT) scan, magnetic resonance cholangio-pancreatography (MRCP) and endoscopic ultrasound (EUS) were performed for all of them; besides, two cases underwent endoscopic retrograde cholangio-pancreatography (ERCP) and placement of a temporary common bile duct stent, four cases underwent EUS-guided fine needle aspiration (EUSFNA) of the pancreas and one case had normal pathologic examination of the specimen harvested during a Whipple operation. Treatment One patient, who was suspected to have cholangiocarcinoma, underwent a Whipple operation, and the other five patients received steroid therapy after they were diagnosed with AIP clinically. They were started on 30 mg/day prednisone orally for 2-4 weeks, which was then reduced to 5 mg for 1-2 weeks, according to their serology and morphology response, followed by a maintenance dosage of 2.5-5.0 mg/day. The total duration of the treatment was 3-4 months. Two of the conservatively treated patients, who had jaundice caused by severe stenosis of the lower part of common bile duct, also had a temporary stent placed. Follow-up During the follow-up of 3-32 months, all six patients were reviewed by BUS, enhanced CT, serum IgG or IgG4, CEA, CA199, ANA periodically in the clinic. RESULTS Patients Four patients complained of mild abdominal pain, mainly at the epigastric region. Five patients demonstrated moderate to severe yellow coloration of the skin and sclera, along with mild tenderness in the upper abdomen. Five patients were found to be anorexic, accompanied with weight loss of 2-8 kg (mean 4.8 kg). All patients denied any history of pancreatitis, trauma or alcoholic addiction. Serology Elevated GPT in five cases (74-648 IU/L), GOT in five cases (125-396 IU/L), γ-GT in five cases (237-2053 IU/L), total bilirubin (mainly direct bilirubin) in five cases (47.7-144.6 μmol/L), fasting blood glucose in four cases (6.18-10.19 mmol/L), amylase in two cases (204-248), CA199 in five cases (80.53-826.9 U/ml), CEA in one case (5.75 ng/ ml), IgG in three cases (1800-4070 mg/dl), IgG4 in two cases (3.85-4.2 g/L) and positive ANA in two cases (1:100 granular pattern and 1:320 homogeneous pattern), ACA in one case (49 RU/ml) were reported. Imaging BUS One case showed low echo mass, with obscure boundary and irregular shape, on the pancreatic body and tail. The other five cases had dilated intrahepatic and extrahepatic bile duct. Of these five cases, two had low echo mass on the pancreatic head, one demonstrated fullness of the pancreatic head, and two reported diffusive swelling of the pancreas with uneven or low echo. CT There was diffusive swelling of the pancreas in five cases and local enlargement on the pancreatic head in one case. In the arterial phase, the affected area was identified as hypoattenuating, but in the late venous phase the area showed increasing hyperintensity (Figures 1A and 1B). There was an incrassate capsule like structure around the pancreas with hypointensity in two patients. Five cases had dilated bile ducts, and four of them had obvious stenosis on the low common bile duct. Swelling lymph nodes were noticed in one case around the pancreatic head and in one case in the retroperitoneal region.Figure 1.: Arterial phase: swelling of pancreatic tail with hypoattenuating, coarse border and a little exudates (A). Venous phase: hyperattenuation of pancreatic tail (B). Venous phase: after 1 week of steroid treatment, swelling diminished (C). Venous phase: enlargement of pancreatic body and tail (D). Venous phase: after 4 weeks of steroid treatment, the enlargement improved (E). MRCP: stenosis of common bile duct and main pancreatic duct (F). MRCP: 4 months later, the stenosis alleviated obviously (G).MRCP All the six patients displayed local or diffusive stenosis of the main pancreatic duct. Four of them showed cutoff of the low common bile duct and dilation of the hepatic bile duct. EUS Five cases had diffusive swelling of the pancreas and one case demonstrated pancreatic head fullness. All the six cases showed local or diffusive stenosis of the main pancreatic duct. Four of them had common bile duct wall thickening and stenosis with dilation of proximal bile ducts. ERCP In two patients, with segmental stenosis of the main pancreatic duct and low common bile duct, a temporary common bile duct stent was placed and steroid therapy was administered. After 2.5 and 3 months respectively, the stent was removed and ERCP revealed obvious improvement of the common bile duct stenosis. Pathology EUS-FNA found no tumor cells in four cases. Pathological findings of one patient who underwent the Whipple operation revealed a gray and yellow-colored pancreas that felt hard. Pancreatic acinar atrophy or disappearance, diffuse interstitial fibrous tissue hyperplasia with multiple plasma cells and lymphocytes infiltration, and visible lymphoid follicle formation could be observed microscopically. Treatment Three patients, who received oral steroid therapy, had remission of symptoms and jaundice in 4 weeks and apparent improvements of pancreatic swelling on CT. Even after 1 week of steroid treatment, the pancreatic enlargement began shrinking on the CT in one patient (Figures 1A-1E). The level of IgG4 dropped down to normal in 4 weeks in two cases. Two patients, who underwent stent placement and steroid therapy, reported normal IgG, CA199 and bilirubin within 1 month. The stent was removed later (2.5, 3 months respectively). MRCP performed at that time showed obvious improvement of the common bile duct stenosis. The lumen of the common bile duct of one patient looked normal on MRCP 4 months later (Figures 1F and 1G). One patient, in whom cholangiocarcinoma was suspected, underwent the Whipple operation. Later, his CA199, bilirubin and fasting blood glucose came down to the normal range. IgG level dropped down to normal in the 32nd month after operation. Follow-up None of the patients showed any relapse, pancreatic carcinoma or cholangiocarcinoma at the end of the follow-up. DISCUSSION Type 1 AIP is called lymphoplasmacytic sclerosing pancreatitis (LPSP) or AIP without granulocyte epithelial lesions (GELs), which prevails in old male patients of Asia, but also occurs in Europeans and North Americans. This type of AIP is an IgG4-related systemic disease with elevated serum IgG4 levels, obstructive jaundice and extrapancreatic lesions (sclerosing cholangitis, sclerosing sialadenitis, and retroperitoneal fibrosis). Consistent with literature reports, our group had four cases of old male patients, five cases complicated with obstructive jaundice and six patients presenting with elevated serum IgG/IgG4. Type 2 AIP is named idiopathic duct-centric pancreatitis (IDCP) or AIP with granulocyte epithelial lesions (AIP with GELs). IDCP and LPSP have some common histopathologic features, such as periductal lymphoplasmacytic infiltrate and storiform fibrosis. Nevertheless, IDCP has a unique pathologic feature called GELs, which is not seen in LPSP. IDCP usually has none or very few (<10 cells/HPF) IgG4-positive plasma cells. Patients with IDCP, mainly in Europe and America, do not show sex predilection and are approximately 16 years younger than LPSP patients. IDCP is not associated with either serum IgG4 elevation or other organ involvement. Approximately 30% of IDCP cases have associated inflammatory bowel disease, such as ulcerative colitis. Because it lacks extrapancreatic organ involvement and specific serology marks, type 2 AIP is definitively diagnosed by pancreatic histology. Sah et al4 found that patients with type 1 AIP have a high relapse rate (47%), but patients with type 2 AIP do not experience relapse. The diagnosis of AIP mainly depends on characteristic imaging findings, serology, histopathology of pancreas, pancreatic organ involvement and response to steroid therapy in the aspect of comprehensive judgment. JPS criteria (2002, 2006 revised edition), Kim criteria (2006) and HISORt criteria of Mayo clinic (2006) are commonly used criteria for the clinical diagnosis of AIP, with a sensitivity of 78%, 96%, and 85%, respectively.5 In order to safely diagnose two different types of AIP and make clinical data comparable, the International Association of Pancreatology developed International Consensus Diagnostic Criteria for AIP in 2011. Typical pancreatic imaging changes are a prerequisite for the diagnosis of AIP. CT of pancreas can show diffusive or focal swelling, sausage shaped enlargement, rim sign and later enhancement, and sometimes pseudocyst, peripancreatic fluids and large vessels impingement. But recently MRI has gained more attention. Another important characteristic of AIP is diffusive or segmental stenosis of the main pancreatic duct. Although MRCP cannot replace ERCP for the diagnostic evaluation of AIP, MRCP plays an important role in the follow-up of patients.6 Endoscopic ultrasonography manifestation of AIP is disputed; however, EUS-FNA can help exclude pancreatic cancer. EUS-TCB acquires core specimens that preserve tissue architecture and permit histological review and diagnosis of AIP. In patients with a pancreatic mass, it is particularly important to differentiate PC. The following combination of signs may be most helpful to differentiate AIP from PC: focal mass combined with swelling of the entire pancreas, duct dilatation accompanied by diffuse duct narrowing, a hypoattenuating rim surrounding the pancreas and late enhancement in dynamic contrast-enhanced MRI or CT. The following ERCP or MRCP findings can confirm the diagnosis of AIP: less obstruction of the MPD, skipped lesions of the MPD, side branch derivation from the narrowed portion of the MPD, length of the narrowed MPD >3 cm, maximal diameter of the upstream <5 mm, smooth stricture of the lower bile duct, and stenosis of intra or hilar bile duct. Serum IgG4 levels are not a definite serology marker for AIP.6 If there is no such typical morphology and lack of serology or extrapancreatic organ involvement, we need to obtain the pancreatic tissue for pathologic diagnosis. EUS-FNA supports diagnosis of AIP by excluding PC with >90% accuracy regardless of the location. KRAS mutation in EUS-FNA material from a pancreatic mass may help discrimination. Two weeks later, the patient's imaging and CA199 should be reassessed. If improvement are observed, the diagnosis of AIP can be confirmed and formal steroid therapy should be continued. Otherwise, explorative operation of the pancreas will be necessary. The preferred treatment of AIP is still oral steroid therapy, and the indication is obstructive jaundice, abdominal pain and/or the presence of symptomatic extrapancreatic disease. The initial dose of prednisolone is 30 or 40 mg/day, but research showed they had no difference in the degree of morphological improvement on imaging and the period of time required to induce remission. Five of our series demonstrated improvements in 4 weeks and full remission in 4 months. Elevated serum IgG4 level and the presence of jaundice were significant independent predictors of relapse in AIP patients. Thus it is appropriate for those patients to prolong the time of corticosteroid treatment and follow-up.